ALPS Medical Breakthroughs ETF (SBIO)Health | Exchange Traded Fund | NYSEArca
65.33 USD
-1.89
(-2.804%) ⇩
(July 13, 2026, 3:45 p.m.
EDT)
After hours: 65.00 -0.33 (-0.335%) ⇩ (July 13, 2026, 6:40 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:51 a.m. EDT
The momentum here is explosive, driven by a biotech sector rebound that pushed this ETF to its 52-week high. The price action over the last two weeks shows relentless buying pressure, closing near the highs despite some minor pullback on the final day. Technically, the asset is trading well above both its 50-day and 200-day averages, confirming a strong uptrend. However, the statistical forecasting model offers zero guidance, citing low reliability and wide confidence intervals, suggesting the recent surge may be driven by noise or temporary sentiment rather than a predictable mean-reversion pattern. While the short-term outlook remains constructive due to the sector catalyst and technical strength, the long-term picture is murky. The fund has suffered a significant drop in value over the last year, erasing previous gains, and the recent annual performance was negative. This indicates the market is currently pricing in a difficult environment for the underlying medical breakthroughs portfolio. Furthermore, the dividend profile is negligible, offering no income cushion to offset the volatility. Investors should view this as a high-beta, momentum play on the biotech recovery rather than a stable long-term holding. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.050192 |
| AutoETS | 0.053966 |
| AutoARIMA | 0.053966 |
| AutoTheta | 0.060946 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 6.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.53 |
As of July 11, 2026, 6:51 a.m. EDT: Speculators are overwhelmingly bullish, evidenced by massive open interest in deep-in-the-money calls (strikes 51-54) relative to puts, which are virtually absent. The implied volatility skew is extreme, with put IV at 4x the call IV, indicating a severe lack of hedging demand and a one-sided speculative bet on continued upside. The flow suggests traders are positioning for a continuation of the recent rally rather than a reversal.
| Date | Dividend | Yield % |
|---|---|---|
| 2024-12-19 | 1.174 | 3.524150 |
| 2023-12-21 | 0.071 | 0.229684 |
| 2019-12-19 | 0.016 | 0.037506 |
| 2018-12-20 | 0.784 | 2.879177 |
| 2017-12-21 | 0.579 | 1.792015 |
| Attribute | Value |
|---|---|
| All Time High | 69.34 |
| All Time Low | 19.18 |
| Ask | 65.5 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 69,250 |
| Average Daily Volume3 Month | 38,757 |
| Average Volume | 38,757 |
| Average Volume10Days | 69,250 |
| Beta3 Year | 0.95 |
| Bid | 60.94 |
| Bid Size | 1,300 |
| Category | Health |
| Crypto Tradeable | 0 |
| Currency | USD |
| Custom Price Alert Confidence | HIGH |
| Day High | 67.18 |
| Day Low | 64.78 |
| Dividend Yield | 0.0 |
| Esg Populated | 0 |
| Exchange | PCX |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 56.37002 |
| Fifty Day Average Change | 8.964878 |
| Fifty Day Average Change Percent | 0.15903628 |
| Fifty Two Week Change Percent | 103.204346 |
| Fifty Two Week High | 69.34 |
| Fifty Two Week High Change | -4.0050964 |
| Fifty Two Week High Change Percent | -0.057760265 |
| Fifty Two Week Low | 32.213 |
| Fifty Two Week Low Change | 33.1219 |
| Fifty Two Week Low Change Percent | 1.0282153 |
| Fifty Two Week Range | 32.213 - 69.34 |
| First Trade Date Milliseconds | 1,420,036,200,000 |
| Five Year Average Return | 0.072728604 |
| Full Exchange Name | NYSEArca |
| Fund Family | ALPS |
| Fund Inception Date | 1,419,897,600 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Has Pre Post Market Data | 1 |
| Language | en-US |
| Legal Type | Exchange Traded Fund |
| Long Business Summary | The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. |
| Long Name | ALPS Medical Breakthroughs ETF |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_275139748 |
| Nav Price | 67.1123 |
| Net Assets | 190,419,616.0 |
| Net Expense Ratio | 0.5 |
| Open | 66.45 |
| Phone | 855.724.0450 |
| Post Market Change | -0.3348999 |
| Post Market Change Percent | -0.5125896 |
| Post Market Price | 65.0 |
| Post Market Time | 1,783,982,448 |
| Previous Close | 67.22 |
| Price Hint | 2 |
| Quote Source Name | Delayed Quote |
| Quote Type | ETF |
| Region | US |
| Regular Market Change | -1.8851 |
| Regular Market Change Percent | -2.80438 |
| Regular Market Day High | 67.18 |
| Regular Market Day Low | 64.78 |
| Regular Market Day Range | 64.78 - 67.18 |
| Regular Market Open | 66.45 |
| Regular Market Previous Close | 67.22 |
| Regular Market Price | 65.3349 |
| Regular Market Time | 1,783,971,901 |
| Regular Market Volume | 75,140 |
| Short Name | ALPS Medical Breakthroughs ETF |
| Source Interval | 15 |
| Symbol | SBIO |
| Three Year Average Return | 0.3043277 |
| Total Assets | 190,419,616 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Trailing Three Month Nav Returns | 23.48676 |
| Trailing Three Month Returns | 23.48676 |
| Triggerable | 1 |
| Two Hundred Day Average | 50.76333 |
| Two Hundred Day Average Change | 14.571571 |
| Two Hundred Day Average Change Percent | 0.28704917 |
| Type Disp | ETF |
| Volume | 75,140 |
| Yield | 0.0 |
| Ytd Return | 26.25697 |